Xovoltib 30 mg Tablet

Description

Xovoltib 30 mg Tablets are manufactured by Boehringer Ingelheim in Germany and contain 30 mg of Afatinib dimaleate (30mg) per tablet. Each Bottle includes 28 tablets per bottle, making Xovoltib 30 mg Tablets an effective option for Lung Cancer . Prescription Required from your healthcare provider to purchase Afatinib dimaleate (30mg) medicine. Indogenmed deals in all type of generic Afatinib dimaleate (30mg) medicine.

Benefits

• Targets EGFR signaling pathways involved in cancer cell growth

• Part of precision oncology therapy based on tumor genetic profiling

• Oral targeted therapy suitable for outpatient treatment

• May help slow disease progression in certain patients with EGFR-mutated NSCLC

• Used as part of modern targeted treatment strategies for lung cancer

Indications and Usage

Xovoltib (afatinib) may be prescribed for:

• Metastatic non-small cell lung cancer (NSCLC) with EGFR mutation

• Patients with tumors confirmed to have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations

• Treatment of advanced lung cancer following appropriate molecular diagnostic testing

Use is determined by an oncologist based on genetic testing results and clinical evaluation.

How it Works

Afatinib works by inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and other members of the ErbB receptor family. These receptors are involved in signaling pathways that regulate cell growth, survival, and proliferation.

In certain lung cancers, mutations in the EGFR gene cause constant activation of these pathways, leading to uncontrolled tumor growth. By blocking these receptors, afatinib disrupts abnormal signaling and may reduce the ability of cancer cells to grow and spread. This targeted mechanism helps slow disease progression when the medicine is used as prescribed and monitored by an oncology specialist.

Dosage & Administration

• Xovoltib tablets are taken orally with water.

• The medicine is usually taken once daily, unless directed otherwise by a healthcare professional.

• Tablets should be taken on an empty stomach (at least 1 hour before or 2 hours after a meal).

• Tablets should be swallowed whole and not crushed or chewed.

• Dose adjustments may be required based on treatment tolerance and side effects.

Side Effects

Common side effects

• Diarrhea

• Skin rash or acne-like rash

• Mouth sores (stomatitis)

• Dry skin

• Decreased appetite

• Nail changes

Serious side effects

• Severe diarrhea leading to dehydration

• Lung inflammation (interstitial lung disease)

• Liver function abnormalities

• Severe skin reactions

• Eye problems such as keratitis

Patients should contact their healthcare provider if severe symptoms occur.

Warning and Precaution

• Risk of severe diarrhea, which may lead to dehydration

• Possible interstitial lung disease (lung inflammation)

• Liver function abnormalities may occur

• Skin reactions and photosensitivity

• Eye disorders such as keratitis

• Inform healthcare providers about all medications and supplements being used

• Pregnancy should be avoided during treatment

Patient Guidance

• Take the medicine exactly as prescribed by your oncologist

• Attend scheduled medical monitoring and laboratory tests

• Report symptoms such as severe diarrhea, breathing difficulty, or skin reactions

• Maintain proper hydration during treatment

• Inform your doctor about all medications and supplements

• Do not stop treatment without consulting your healthcare provider

Clinical Trial & Approvals

Afatinib has been evaluated in clinical trials for patients with EGFR mutation–positive non-small cell lung cancer. Studies such as the LUX-Lung clinical trials demonstrated improved outcomes in certain patients with EGFR-mutated NSCLC compared with earlier therapies. Based on these findings, afatinib received regulatory approvals from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific lung cancer indications.

References